Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain
Status:
Terminated
Trial end date:
2021-02-16
Target enrollment:
Participant gender:
Summary
The primary objective of this extension study is to assess the maintenance of efficacy of
linzagolix administered orally once daily for up to an additional 6 months (for up to 12
months of treatment in total) in women who have already completed 6 months of linzagolix
treatment at a dose of 75 mg alone or of 200 mg in combination with ABT (E2 1 mg / NETA 0.5
mg), in the management of moderate to severe endometriosis-associated pain (EAP) in women
with surgically confirmed endometriosis.